Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

News | Pharmaceuticals | Dave Fornell, Editor

Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran ...

March 28, 2020

Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA

News | Womens Cardiovascular Health

Sex Differences in Stress Test and CCTA Findings and Symptoms in the Ischemia Trial

March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia) ...

March 28, 2020

News | Heart Failure

Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse ...

March 28, 2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

News | Antiplatelet and Anticoagulation Therapies

Antiplatelet Genetic Testing Missed Goal to Cut Cardiovascular Events in Half

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to ...

March 28, 2020

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

March 28, 2020

Videos | Coronavirus (COVID-19)

VIDEO: What Cardiologists Need to Know about COVID-19

Interview with Thomas Maddox, M.D., MSc, FACC, the chairman of the American College of Cardiology (ACC) Science and ...

March 17, 2020

Videos | Heart Failure

VIDEO: Occluding the SVC as a Reset Button in Heart Failure

Interview with Navin Kapur, M.D., FAHA, FACC, FSCAI, executive director, The CardioVascular Center for Research and ...

March 13, 2020

Feature | ACC | Dave Fornell, Editor

ACC Cancels 2020 Conference Amid Coronavirus Concerns

March 9, 2020 — Less than week after the American College of Cardiology (ACC) said it would push ahead with holding its ...

March 09, 2020

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry #Amyloidosis

News | Cardiac Diagnostics

Amyloidosis Patient Registry Hits 300 Participants and Now Open to Entire Community

March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the ...

March 05, 2020

Aria CV Pulmonary Hypertension System_Aria CV PH System

News | Hypertension

Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study

February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study in ...

February 27, 2020

Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.

News | Stents

Biotronik's Orsiro Stent Continues Excellent Results After Three Years

February 24, 2020 — Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the ...

February 24, 2020

A 3-D rendering created from the chest CT scan of a 41-year-old coronavirus patient in China showing ground-glass opacities in several areas of the lungs from the coronavirus pneumonia. This was from one of the first medical imaging studies published on COVID-19 in the journal Radiology. #coronavirus #COVID2019 #COVID19 #2019nCoV #SARS‐CoV‐2

Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

The Cardiac Implications of Novel Coronavirus

(Article updated May 27, 2020)

February 20, 2020 — The American College of Cardiology (ACC) released a clinical ...

February 20, 2020

The DEFINE GPS (Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting) study will be the first time that the use of iFR in conjunction with the Philips Image-Guided Co-registration System (SyncVision) is evaluated for PCI guidance and the optimization of treatment outcomes.

News | Cath Lab Navigation Aids

DEFINE GPS Study Assesses PCI Guided by Integrated iFR and Angiography

February 12. 2020 — Philips announced a new randomized controlled trial to assess patient outcomes after receiving a ...

February 12, 2020

Videos | Hemodynamic Support Devices

VIDEO: Door-to-Unloading (DTU) Trial May Change STEMI Care

Interview with Navin Kapur, M.D., FAHA, FACC, FSCAI, executive director, The CardioVascular Center for Research and ...

February 07, 2020

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system, left, became the first TMVR device to gain commercial regulatory clearance in the world. It gains European CE mark in January. Another top story in January was the first use of the Robocath R-One robotic cath lab catheter guidance system in Germany. Watch a VIDEO of the system in use in one of those cases.

News | Dave Fornell, Editor

February 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) m ...

February 03, 2020